Singly

High-Level Overview

Single Technologies is a biotechnology company developing 3-D Sequencing™ technology to eliminate bottlenecks in generating sequencing data, empowering scientists with AI to tackle complex biological problems.[1] Their flagship product, Theta, is the world's first 3-D sequencer, enabling unprecedented throughput for massive parallelism in both in situ and solution-based DNA sequencing, ideal for short-read applications and soon available for testing.[1] The company serves omics innovators, researchers, and companies by providing tools that foster breakthroughs in DNA analysis, addressing limitations in traditional sequencing speed and scale to accelerate scientific discovery.[1]

Origin Story

Single Technologies was founded by Johan Strömqvist, who serves as CEO.[1] While specific founding year details are unavailable in current sources, the company's emergence aligns with advances in spatial omics and AI-driven biology, where Strömqvist's leadership has positioned it to pioneer 3-D sequencing as a foundational platform for next-generation applications.[1] Early focus on collaborating with innovators highlights a pivotal strategy to build an ecosystem around their technology from inception.[1]

Core Differentiators

• 3-D Sequencing™ Platform: Unlike conventional 2D methods, Theta enables sequencing in three dimensions for higher throughput and massive parallelism, supporting both in situ (tissue-preserved) and solution-based workflows.[1]
• AI Empowerment for Scientists: Removes data generation bottlenecks, allowing AI integration to solve intricate biological challenges with more reads than ever before.[1]
• Ecosystem Partnerships: Commits to supporting leading researchers and companies building applications on their platform, fostering innovation through tools and collaboration.[1]
• Upcoming Accessibility: Theta positioned for imminent testing, emphasizing speed to market for short-read applications.[1]

Role in the Broader Tech Landscape

Single Technologies rides the spatial omics and multi-omics wave, where demand for high-throughput, spatially resolved sequencing is exploding amid AI's rise in biology.[1] Timing is ideal as falling sequencing costs and AI models demand faster data generation, with market forces like precision medicine and drug discovery favoring scalable platforms like 3-D sequencing over legacy technologies.[1] By partnering with innovators, it influences the ecosystem, enabling downstream applications that redefine research and potentially accelerating breakthroughs in genomics and personalized therapies.[1]

Quick Take & Future Outlook

Single Technologies is poised to disrupt sequencing with Theta's launch, scaling 3-D capabilities to meet AI-biology convergence demands. Trends like agentic AI in research and expanding omics datasets will propel growth, potentially evolving its role from tool provider to ecosystem orchestrator. As bottlenecks dissolve, expect broader influence in redefining biological problem-solving, building on its visionary foundation.[1]